Added to YB: 2026-10-02
Pitch date: 2026-09-22
NOVO-B.CO [neutral]
Novo Nordisk A/S
+2.91%
current return
Author Info
Lux Opes Research covers European companies. Lots of them. Sign up for the newsletter.
Company Info
Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products.
Market Cap
DKK 1.1T
Pitch Price
DKK 256.00
Price Target
N/A
Dividend
4.56%
EV/EBITDA
7.01
P/E
9.79
EV/Sales
3.73
Sector
Pharmaceuticals
Category
growth
Novo Nordisk (NOVOB Denmark): Pipeline takes centre stage
NOVO-B.CO (update): Novo Nordisk expects ~5% annual sales growth through 2030 with broadly stable operating margins. It is preparing for at least five blockbuster launches and wants its pipeline to generate DKK150bn of sales by 2035. Semaglutide still exceeds 70% of group sales, while increasing obesity and diabetes competition heightens the need for new products. CagriSema has not established an efficacy advantage over tirzepatide, and several potential 2030s growth drivers remain clinically unproven.
Read full article (2 min)